IPO Year:
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/2/2025 | $12.00 | Buy | TD Cowen |
8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
10-K - Grace Therapeutics, Inc. (0001444192) (Filer)
SCHEDULE 13G - Grace Therapeutics, Inc. (0001444192) (Subject)
SCHEDULE 13G/A - Grace Therapeutics, Inc. (0001444192) (Subject)
8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
EFFECT - Grace Therapeutics, Inc. (0001444192) (Filer)
S-3 - Grace Therapeutics, Inc. (0001444192) (Filer)
8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
D - Grace Therapeutics, Inc. (0001444192) (Filer)
10-Q/A - Grace Therapeutics, Inc. (0001444192) (Filer)
TD Cowen initiated coverage of Grace Therapeutics with a rating of Buy and set a new price target of $12.00